A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial.
By J. Ormiston, Patrick W. Serruys, E. Regar, D. Dudek, L. Thuesen, M. Webster, Y. Onuma, H. Garcia-Garcia, R. McGreevy, S. Veldhof. The Lancet, 2008
728 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging, Surgery
View Paper: https://www.semanticscholar.org/paper/cb7501cdbe9f7edb7eb04f378559ed7c4a962033
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Radiology, Nuclear Medicine and Imaging
In Surgery
Citations in the corpus
- CONSORT 2010 statement: extension to randomised pilot and feasibility trials (2016, neutral): “Procedural success was 100 % (30/30 patients), and device success 94 % (29/31 attempts at implantation of the stent) [78].”
- Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. (2012, background): “(9) (preserved box, open box, dissolved bright box, and dissolved black box) for one type of bioabsorbable scaffold.”